Targeting AR Variant-Coactivator Interactions to Exploit Prostate Cancer Vulnerabilities

This study demonstrates the potential therapeutic utility of inhibiting constitutively active AR-V signaling by disrupting coactivator binding. Such an approach is significant, as AR-Vs are emerging as important drivers of CRPC that are particularly recalcitrant to current therapies. Mol Cancer Res; 15(11); 1469–80. ©2017 AACR.
Source: Molecular Cancer Research - Category: Cancer & Oncology Authors: Tags: Cell Death and Survival Source Type: research